Myth-buster
A double-blind trial of 153 women with early-onset preeclampsia found that 600 mg/day of N-acetylcysteine did not significantly delay progression to severe disease — casting doubt on hopes for a low-cost option in resource-limited settings.
This is one of the first randomized trials testing NAC for this condition; the null result suggests it is not effective in this population, but the body of evidence is still too thin to draw a final conclusion.
Preeclampsia is a dangerous pregnancy complication characterized by high blood pressure and organ damage. In this 153-woman trial, researchers measured how quickly early-onset preeclampsia worsened, comparing women who took 600 mg of NAC daily to those on placebo. The supplement showed no statistically significant advantage in slowing the disease's progression.
Where this fits in the evidence
This is among the first studies we've indexed on N-Acetyl Cysteine for Reduced Time-to-Disease Progression — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 153
- 2026-06-17
- PloS one
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.